630 related articles for article (PubMed ID: 31693057)
21. Management and outcomes of hypertrophic cardiomyopathy in young adults.
Baron É; Karam N; Donal E; Puscas T; Mirabel M; Bacher A; Wahbi K; Mazzella JM; Jeunemaitre X; Reant P; Hagège A;
Arch Cardiovasc Dis; 2021; 114(6-7):465-473. PubMed ID: 33744178
[TBL] [Abstract][Full Text] [Related]
22. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.
Maron MS; Olivotto I; Betocchi S; Casey SA; Lesser JR; Losi MA; Cecchi F; Maron BJ
N Engl J Med; 2003 Jan; 348(4):295-303. PubMed ID: 12540642
[TBL] [Abstract][Full Text] [Related]
23. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
24. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction.
Desai MY; Bhonsale A; Smedira NG; Naji P; Thamilarasan M; Lytle BW; Lever HM
Circulation; 2013 Jul; 128(3):209-16. PubMed ID: 23770748
[TBL] [Abstract][Full Text] [Related]
25. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
26. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy.
Killu AM; Park JY; Sara JD; Hodge DO; Gersh BJ; Nishimura RA; Asirvatham SJ; McLeod CJ
Europace; 2018 Jan; 20(1):82-88. PubMed ID: 29315424
[TBL] [Abstract][Full Text] [Related]
27. Incidence, Clinical Characteristics, and Long-term Outcome of the Dilated Phase of Hypertrophic Cardiomyopathy.
Aizawa Y; Tanimoto Y; Hirata Y; Fujisawa T; Fukuoka R; Nakajima K; Katsumata Y; Nishiyama T; Kimura T; Yuasa S; Kohno T; Kohsaka S; Murata M; Maekawa Y; Furukawa Y; Takatsuki S; Fukuda K
Keio J Med; 2019 Dec; 68(4):87-94. PubMed ID: 30606897
[TBL] [Abstract][Full Text] [Related]
28. Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure.
Akhtar MM; Lorenzini M; Pavlou M; Ochoa JP; O'Mahony C; Restrepo-Cordoba MA; Segura-Rodriguez D; Bermúdez-Jiménez F; Molina P; Cuenca S; Ader F; Larrañaga-Moreira JM; Sabater-Molina M; Garcia-Alvarez MI; Arantzamendi LG; Truszkowska G; Ortiz-Genga M; Ruiz IS; Nielsen SK; Rasmussen TB; Robles Mezcua A; Alvarez-Rubio J; Eiskjaer H; Gautel M; Garcia-Pinilla JM; Ripoll-Vera T; Mogensen J; Limeres Freire J; Rodríguez-Palomares JF; Peña-Peña ML; Rangel-Sousa D; Palomino-Doza J; Arana Achaga X; Bilinska Z; Zamarreño Golvano E; Climent V; Peñalver MN; Barriales-Villa R; Charron P; Yotti R; Zorio E; Jiménez-Jáimez J; Garcia-Pavia P; Elliott PM;
JAMA Cardiol; 2021 Aug; 6(8):891-901. PubMed ID: 33978673
[TBL] [Abstract][Full Text] [Related]
29. Association of the Obesity Paradox With Objective Physical Activity in Patients at High Risk of Sudden Cardiac Death.
Li X; Chen K; Hua W; Su Y; Yang J; Liang Z; Xu W; Xue X; Zhang S; Zhao S
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942298
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction.
Rowin EJ; Maron BJ; Carrick RT; Patel PP; Koethe B; Wells S; Maron MS
J Am Coll Cardiol; 2020 Jun; 75(24):3033-3043. PubMed ID: 32553256
[TBL] [Abstract][Full Text] [Related]
31. Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations.
Coppini R; Ho CY; Ashley E; Day S; Ferrantini C; Girolami F; Tomberli B; Bardi S; Torricelli F; Cecchi F; Mugelli A; Poggesi C; Tardiff J; Olivotto I
J Am Coll Cardiol; 2014 Dec; 64(24):2589-2600. PubMed ID: 25524337
[TBL] [Abstract][Full Text] [Related]
32. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy.
Olivotto I; Maron MS; Adabag AS; Casey SA; Vargiu D; Link MS; Udelson JE; Cecchi F; Maron BJ
J Am Coll Cardiol; 2005 Aug; 46(3):480-7. PubMed ID: 16053962
[TBL] [Abstract][Full Text] [Related]
33. Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy.
Sridharan A; Maron MS; Carrick RT; Madias CA; Huang D; Cooper C; Drummond J; Maron BJ; Rowin EJ
J Cardiovasc Electrophysiol; 2022 Jan; 33(1):20-29. PubMed ID: 34845799
[TBL] [Abstract][Full Text] [Related]
34. Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy.
Pasqualucci D; Fornaro A; Castelli G; Rossi A; Arretini A; Chiriatti C; Targetti M; Girolami F; Corda M; Orrù P; Matta G; Stefàno P; Cecchi F; Porcu M; Olivotto I
Circ Heart Fail; 2015 Nov; 8(6):1014-21. PubMed ID: 26446673
[TBL] [Abstract][Full Text] [Related]
35. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.
Hamada T; Kubo T; Kitaoka H; Hirota T; Hoshikawa E; Hayato K; Shimizu Y; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Takata J; Doi YL
Clin Cardiol; 2010 Jul; 33(7):E24-8. PubMed ID: 20641106
[TBL] [Abstract][Full Text] [Related]
36. Friedreich's ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study.
Norrish G; Rance T; Montanes E; Field E; Brown E; Bhole V; Stuart G; Uzun O; McLeod KA; Ilina M; Adwani S; Daubeney P; Delle Donne G; Linter K; Jones CB; Bharucha T; Cervi E; Kaski JP
Arch Dis Child; 2022 May; 107(5):450-455. PubMed ID: 34610949
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy).
Nistri S; Olivotto I; Betocchi S; Losi MA; Valsecchi G; Pinamonti B; Conte MR; Casazza F; Galderisi M; Maron BJ; Cecchi F
Am J Cardiol; 2006 Oct; 98(7):960-5. PubMed ID: 16996883
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
[TBL] [Abstract][Full Text] [Related]
39. Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function.
Aleong RG; Mulvahill MJ; Halder I; Carlson NE; Singh M; Bloom HL; Dudley SC; Ellinor PT; Shalaby A; Weiss R; Gutmann R; Sauer WH; Narayanan K; Chugh SS; Saba S; London B
J Am Heart Assoc; 2015 Jul; 4(8):e001566. PubMed ID: 26231842
[TBL] [Abstract][Full Text] [Related]
40. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
